236350e9-8964-42ae-8880-d2f2281ff993
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.500
- G2M_CHECKPOINT+0.500
- MYC_TARGETS_V1+0.500
- MYC_TARGETS_V2+0.500
- MITOTIC_SPINDLE+0.400
- PROTEIN_SECRETION+0.400
- UNFOLDED_PROTEIN_RESPONSE+0.300
- CHOLESTEROL_HOMEOSTASIS+0.200
- DNA_REPAIR+0.200
- MTORC1_SIGNALING+0.200
Top 10 suppressed
- ANGIOGENESIS-0.600
- IL6_JAK_STAT3_SIGNALING-0.600
- INTERFERON_ALPHA_RESPONSE-0.600
- INTERFERON_GAMMA_RESPONSE-0.600
- ALLOGRAFT_REJECTION-0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
- INFLAMMATORY_RESPONSE-0.500
- COAGULATION-0.400
- COMPLEMENT-0.400
- IL2_STAT5_SIGNALING-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SAMN03290927 | — | — | 0.929 |
| 2 | 20120209.TNBC | — | E | 0.927 |
| 3 | TCGA-O2-A5IB-01A-11R-A27Q-07 | — | cohortMD1 | 0.926 |
| 4 | SRR8518295 | — | E | 0.924 |
| 5 | SRR1797283 | — | cohortSC | 0.924 |
| 6 | C3L-02649 | — | cohortMD1 | 0.917 |
| 7 | AUR-AFR3-TTM1-A-1-1-R-A743-41 | — | C | 0.917 |
| 8 | R6 | — | — | 0.917 |
| 9 | ERR2598229 | fetal | fetal | 0.916 |
| 10 | BS_1HQ76V6D | Embryonal tumors | — | 0.915 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.500 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.400 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |